



ALTERNATIVE TO PTO/SB/08A/B  
(Based on PTO 01-08 version)

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/748,541
				Filing Date	December 29, 2003
				First Named Inventor	Vibeke STRAND
				Art Unit	1644
				Examiner Name	G. Ewoldt
Sheet	1	of	1	Attorney Docket Number	252312007900

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	1.	La Jolla Pharmaceutical Co. (November 14, 2005). "La Jolla Pharmaceutical Company Presents at American College of Rheumatology Annual Scientific Meeting," located at < <a href="http://www.ljpc.com/pressrelease/1114_05.htm">http://www.ljpc.com/pressrelease/1114_05.htm</a> >, last visited on February 25, 2008, 3 pages.		
	2.	Letter from Robert Temple of the United States Food and Drug Administration (Director of the Office of Drug Evaluation I, Center for Drug Evaluation and Research) (October 13, 2004). Addressed to La Jolla Pharmaceutical Company, approving the new drug application (NDA) dated December 14, 2003, 2 pages.		
	3.	Non-Final Office Action mailed on March 19, 2007, for U.S. Patent Application No. 10/219,238, 9 pages.		
	4.	Non-Final Office Action mailed on August 22, 2007, for U.S. Patent Application No. 11/373,699, 11 pages.		
	5.	Non-Final Office Action mailed on August 31, 2007 for U.S. Patent Application No. 11/613,987, 11 pages.		
	6.	Final Office Action mailed on November 14, 2007, for U.S. Patent Application No. 10/814,555, 9 pages.		
	7.	TUMLIN, J.A. et al. (2004). "Reductions in 24-Hour Urine Protein Levels Associated with Treatment of SLE Patients with LJP394 in Two Randomized, Placebo-Controlled Clinical Trials," abstract presented at the American Society of Nephrology Annual Scientific Meeting, St. Louis, MO, October 27-November 1, 2004, located at < <a href="http://www.ljpc.com/abstracts/abstract_2004_18.html">http://www.ljpc.com/abstracts/abstract_2004_18.html</a> >, last visited on February 14, 2008, 2 pages.		
Examiner Signature			Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.